REG - Kromek Group PLC - PDMR/Director Shareholding, Issue of Equity & TVR

KromekAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260601:nRSA3319Ga&default-theme=true

RNS Number : 3319G  Kromek Group PLC  01 June 2026

1 June 2026

 

Kromek Group plc

("Kromek", the "Company" or the "Group")

 

PDMR/Director Shareholding, Issue of Equity and Total Voting Rights

 

Kromek (AIM: KMK), a global detection company delivering best-in-class
solutions for the advanced imaging and CBRN detection markets, announces that
it has issued and allotted a total of 163,071 ordinary shares of 1p each in
the Company ("Ordinary Shares") to satisfy the exercise of options by
employees of the Company. This includes the exercise of 150,000 options by
Berry Beumer, an Executive Director of the Company, on 28 May 2026. Following
this exercise, Mr. Beumer has an interest in 230,000 Ordinary Shares,
representing 0.03% of the Company's enlarged issued share capital.

 

Total voting rights

 

Application has been made to the London Stock Exchange for the 163,071
Ordinary Shares to be admitted to trading on AIM ("Admission") and it is
expected that Admission will become effective at 8 a.m. on or around 4 June
2026. The new Ordinary Shares will rank pari passu with the existing Ordinary
Shares in the Company.

 

Following Admission, the total number of Ordinary Shares in issue will be
655,299,911. This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.

 

Enquiries

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Claire Burgess, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Andrew Burdis - ECM

 Michael Johnson - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury                                           +44 (0)20 4582 3500

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

 In CBRN detection, the Group provides nuclear radiation detection solutions
to the global homeland defence and security market. Kromek's compact,
handheld, high-performance radiation detectors, based on advanced
scintillation and solid-state readout technology, are primarily used to
protect critical infrastructure, events, personnel and urban environments from
the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

Notification and public disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with them

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Berry Beumer

 2    Reason for the notification

 a)   Position/status                                              Chief Operating Officer and President of the Advanced Imaging Division

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Kromek Group plc

 b)   LEI                                                          213800VLHYXGHEX5VQ48

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Options over ordinary shares of 1 penny each

      Identification code                                          GB00BD7V5D43

 b)   Nature of the transaction                                    Exercise of options

 c)   Price(s) and volume(s)

                                                                                       Price(s)            Volume(s)
                                                                                       1p                  150,000

 d)

      Aggregated information                                       N/A

      -      Aggregated volume

      -      Price

 e)   Date of the transaction                                      28 May 2026

 f)   Place of the transaction                                     Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEBLFXQELBBBZ



            Copyright 2019 Regulatory News Service, all rights reserved